

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**( 深圳市海普瑞藥業集團股份有限公司 )**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**RESIGNATION OF EXECUTIVE DIRECTOR  
AND CHANGE OF FINANCIAL CONTROLLER**

**RESIGNATION OF EXECUTIVE DIRECTOR AND FINANCIAL CONTROLLER**

The board of directors (the “**Board**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) hereby announces that Mr. Zhang Bin (“**Mr. Zhang**”) has resigned from his position with effect from 29 April 2022 as an executive director and financial controller of the Company due to other work arrangements, which require more of his time and commitment. Mr. Zhang has confirmed that he has no disagreement with the Board and that there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. The Board hereby expresses its sincere gratitude to Mr. Zhang for his dedication, diligence and valuable contributions to the Company during his tenure of service.

**APPOINTMENT OF FINANCIAL CONTROLLER**

The Board is pleased to announced that Mr. Xiang Xianqing (“**Mr. Xiang**”) has been appointed as the financial controller of the Company with effect from 29 April 2022. The biographical details of Mr. Xiang are set out below:

Mr. Xiang, aged 47, obtained a bachelor's degree in accounting from Jinan University, and an EMBA from China Europe International Business School. He is a member of CPA Australia. He has over 23 years of experience in financial management of large and medium-sized enterprises. He has worked in well-known multinational companies including General Electric Company in the United States of America, and ThyssenKrupp AG in Germany. During 2008 to 2011, he served as the chief financial officer of the Asia-Pacific region of Chiquita Brands International Inc. From 2011 to 2013, he served as the vice president and chief financial officer of JK Yaming International Holdings. During the period between 2013 to 2016, he was the director of the financial department of the international headquarter of Midea Group. From 2016 to 2018, he served as the vice president and chief financial officer of Guangdong Dongfang Precision Technology Co., Ltd.\* (廣東東方精工科技股份有限公司). From 2019 to 2021, he served as the deputy general manager, board secretary and chief financial officer of Guangzhou Huayinkang Medical Group Co., Ltd.\* (廣州華銀康醫療集團股份有限公司).

The Board would like to express its warmest welcome to Mr. Xiang.

Announcement is hereby given.

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, the PRC  
April 29, 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*

\* *The English names are translation and/or transliteration of their Chinese names and have been included in this announcement for identification purposes only. In the event of any inconsistency between the Chinese names and their English translations and/or transliterations, the Chinese versions shall prevail.*